RAMM Pharma Corp. announced that the company has entered into a definitive acquisition agreement with Canapar Corp. and a wholly-owned subsidiary of the Company on May 11, 2021, that provides for the acquisition of all the common shares of Canapar (“Canapar Shares”) that the Company does not currently own in exchange for an aggregate of approximately 21,904,095 common shares RAMM at a deemed value of $1.20 per Ramm Share (“RAMM Shares”) for a total purchase price of approximately $26.2 million (the “Transaction”). On closing of the Transaction, Sergio Martines, the current Chief Executive Officer of Canapar, will be appointed to the board of directors of RAMM. Matthew Bajurny has also stepped down from the board.